Mereo BioPharma Group PLC MREO.OQ, MREO.O is expected to show a rise in quarterly revenue when it reports results on November 10 (estimated) for the period ending September 30 2025
The London United Kingdom-based company is expected to report revenue of $11.667 million, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Mereo BioPharma Group PLC is for a loss of 2 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Mereo BioPharma Group PLC is $7.00, about 74.9% above its last closing price of $1.76
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.01 | -0.02 | -0.10 | Missed | -511.6 |
Mar. 31 2025 | -0.02 | -0.01 | -0.10 | Missed | -1,304.2 |
Dec. 31 2024 | -0.02 | -0.01 | -0.05 | Missed | -229.5 |
Sep. 30 2024 | -0.02 | -0.02 | -0.10 | Missed | -460.6 |
Jun. 30 2024 | -0.01 | -0.01 | -0.10 | Missed | -906.4 |
0.00 | | ||||
Dec. 31 2023 | 0.00 |
This summary was machine generated November 7 at 16:00 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments